Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration  Felicity C. Smith, BMedSci (Hons), Shaun S. Kumar, PhD, Timothy J. Furlong, PhD, Suraj V. Gangaram, BMedSci (Hons), Jerry R. Greenfield, PhD, Sophie L. Stocker, PhD, Garry G. Graham, PhD, Kenneth M. Williams, PhD, Richard O. Day, MD  American Journal of Kidney Diseases  Volume 68, Issue 6, Pages 990-992 (December 2016) DOI: 10.1053/j.ajkd.2016.08.017 Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Average metformin plasma concentrations entering the hemodiafilter before and after dose changes in patients with T2DM receiving HDF. Samples were collected before the hemodiafilter at the start of the HDF session, during, and at the end of HDF for all patients (n=4 time points). All patients were initiated on 500mg of metformin after HDF (1,500mg/wk). At the start of week 5 and 6, the metformin dose was decreased to 500mg once weekly for patients 1 and 2, respectively (taken after HDF), and to 250mg after HDF (750mg/wk) at week 7 and 8 for patients 3 and 4, respectively. American Journal of Kidney Diseases 2016 68, 990-992DOI: (10.1053/j.ajkd.2016.08.017) Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions